Clinical Trial Update: A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants [Phase 1]

View source ↗

Summary

Phase 1b/2a randomized, double-blind, placebo-controlled study evaluating MEDI8897 in healthy preterm infants; completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus

Drugs mentioned

• MEDI8897

Snippet

Sponsor: MedImmune LLC | Conditions: Respiratory Syncytial Virus | Phase 1 | Status: COMPLETED | Results posted: 2018-09-19